Skip to main content
. 2022 Feb 22;12(4):1825–1839. doi: 10.1016/j.apsb.2022.02.014

Figure 4.

Figure 4

Low dose of osimertinib leads to marked survival benefits and increased tumor necrosis in mouse CRC models. (A) Left, volume of subcutaneous MC38 tumors treated with vehicle or osimertinib (1 mg/kg) daily for 14 days by oral gavage. Right, tumor weight at necropsy. (B) Kaplan–Meier survival curves of two indicated groups. (C) Left, volume of subcutaneous CT26 tumors in two indicated groups treated as (A). Right, tumor weight at necropsy. Statistical analysis by unpaired Student's t-test. (D) Left, representative images of Ki67 immunostaining and nuclear staining of MC38 tumors in two indicated groups. Right, quantitative analysis of the relative nuclear Ki67 in vehicle group and osimertinib group. Each dot indicates one tumor and represents the average of 5 images. n = 8. (E) Left, representative images of cleaved caspase-3 (CC3) staining (orange) and 4′,6-diamidino-2-phenylindole (DAPI) nuclear staining (blue) of MC38 tumors in two indicated groups. Right, quantitative analysis of the relative cell death in vehicle group and osimertinib group. Each dot indicates one tumor per mouse and represents the average of 5 images. n = 8. Statistical analysis by unpaired Student's t-test or log-rank test. Data are mean ± SEM. Scale bar = 100 μm.